After a massive slip up last year, the tide appears to be turning for small cap vaccine maker Novavax (NVAX). In Wednesday’s trading session, shares took off and surged as much as 15% after the company announced that it had received fast-track designation from the FDA for its NanoFlu vaccine in adults at least 65 years old.CEO Stanley Erck stated that the designation “reflects the urgent unmet medical need for a more effective vaccine against influenza, particularly in the older adult population which often experiences serious and sometimes life-threatening complications, of the disease.”The news comes as a pleasant surprise for …read more
Source:: Yahoo Finance
